Minoryx is a drug development company specializing in the discovery of new drugs for orphan diseases. The company targets Inborn Errors of Metabolism; a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) that has multiple CNS indications. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurologic deterioration with no available pharmacological treatment. Minoryx is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – SEE-Tx.
The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.